Although there is still disagreement on whether SGLT2 inhibitors can enhanced myocardial work efficiency (Ho et al., 2019; Horton et al., 2019; Santos-Gallego et al., 2019), it is certain that SGLT2 inhibitors can supply the extra fuel and change the state of “energy hunger” in failing heart. This evidence concerns the gene SLC5A2 and benign neoplasm.